Many biotech startups are spending money from investors and grants by the billions, in an effort to find new ways of treating humans, but some of them have chosen to focus their attention on animals. Bioceltix does business on this developing market of veterinary products. Developing innovative biopharmaceuticals designed to treat ailments commonly experienced by animals.
To do this the company uses the immunomodulatory properties of mesenchymal stem cells (the potential of which is still underutilized when it comes to veterinary applications). The market for veterinary biopharmaceuticals has been practically stagnant for years – it’s just 2 years ago that the biotech drug was officially registered by the European Medicines Agency (EMA). We are responding to market needs – offering pet owners an alternative to the currently available standard (and often ineffective) methods of treatment based on xenobiotics – says – Łukasz Bzdzion, CEO of Bioceltix.
More.